Telix Releases Results for the Year Ended 31 December 2021 and 2021 Annual Report
Melbourne (Australia) – 24 February 2022. Telix Pharmaceuticals Limited Releases Full-Year 2021 Results and 2021 Annual Report.
Telix is pleased to present a Shareholder Update for the year ended 31 December 2021, and 2021 Annual Report.
In 2021, Telix transitioned to a commercial company with the approval of our first product, Illuccix, in Australia and the United States. In 2022 we will build on this platform as we prepare to file two additional new drug applications with the United States FDA for kidney cancer imaging (TLX250-CDx) and brain cancer imaging (TLX101-CDx).
Every day, people around the globe benefit from the impact of our R&D, and now with our first commercial product, this impact will be even greater. This is reflected in our purpose to help people with cancer and rare diseases live longer, better quality lives; a purpose Telix believes is as important to shareholders as it is to our employees.
We wish to thank all our collaborators, shareholders, and staff for ongoing support, and we look forward to delivering on our corporate objectives for 2022.
To view Telix’s 2021 Annual Report please click here.
The Shareholder Update was recorded and is now available on-demand below
The Shareholder Update was recorded and is now available for on-demand public viewing here or listen to the recording below.Audio Player